Investors & Media

press releases

There are currently no events to display.
Date Title Teaser
06/15/18
Summary Togglebluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association

– All patients (n=4) in Group C with ≥ 3 months follow-up consistently producing ≥ 30% anti-sickling HbA T87Q – – First Group C patient generating a normal total hemoglobin of 14.2 g/dL with over 60% anti-sickling HbA T87Q at 6 months – – Company to hold conference call and webcast today, June 15 ,

06/15/18
Summary Togglebluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association

– 7/8 non-β 0 /β 0 patients with ≥ 6 months follow-up producing normal or near-normal amounts of total hemoglobin (11.1 – 13.3 g/dL) and are transfusion free in Northstar-2 Study – – 8/10 of non-β 0 /β 0 patients achieving and maintaining transfusion independence for up to 3 years in Northstar

06/05/18
Summary Togglebluebird bio Announces Investor Events in June

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 5, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences in June: Jefferies Global Healthcare Conference , Thursday, June 7 , at 10:00 a.m.

06/01/18
Summary ToggleUpdated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting High rates of response that were both deep and durable were seen at the highest dose levels. Median PFS of approximately one year achieved in heavily pre-treated patients in the active doses of the dose escalation cohort Consistent response observed for both low and high BCMA expression levels
05/23/18
Summary ToggleFDA Grants Breakthrough Therapy Designation to Lenti-D™ for the Treatment of Cerebral Adrenoleukodystrophy

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 23, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration ( FDA ) has granted Breakthrough Therapy designation to Lenti-D™ for the treatment of patients with cerebral adrenoleukodystrophy (CALD), a rare, serious

05/17/18
Summary Togglebluebird bio to Present New Data from LentiGlobinTM Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association

- Oral presentation of updated data from Phase 3 Northstar-2 (HGB-207) study of LentiGlobin in patients with transfusion-dependent β-thalassemia (TDT) and non-β 0 /β 0 genotypes – - Oral presentation of interim data from patients treated with updated study protocol of Phase 1 HGB-206 study of

05/16/18
Summary Togglebluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting

– Presentation will include safety and efficacy data from 21 patients treated in dose-escalation phase and early data from patients treated in dose-expansion phase – – Additional poster exploring the significance of MRD negativity in patients in this study to be presented – – Company to host

05/08/18
Summary Togglebluebird bio to Present at Investor Conferences in May

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: Deutsche Bank’s 43 rd Annual Health Care Conference , Wednesday, May 9 , at 10:00 a.m.

05/02/18
Summary Togglebluebird bio Reports First Quarter 2018 Financial Results and Highlights Operational Progress

– Completed Northstar study of LentiGlobin in transfusion dependent β-thalassemia (TDT) – – Entered into co-development and co-promotion agreement for bb2121 with Celgene – – Ended quarter with $1.57 billion in cash, cash equivalents and marketable securities – CAMBRIDGE, Mass.

04/18/18
Summary Togglebluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobinTM Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia

– Majority (12/13) of patients with non-β 0 /β 0 genotypes were transfusion-free at median 27 months following LentiGlobin treatment – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 18, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) today announced interim data published in the New England Journal of Medicine

04/16/18
Summary Togglebluebird bio to Present at Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 16, 2018-- bluebird bio, Inc. (Nasdaq:BLUE) today announced that members of the management team will present at Alliance for Regenerative Medicine’s 6 th Annual Cell & Gene Therapy Investor Day on Tuesday, April 17 , at 11:25 a.m.

03/28/18
Summary Togglebluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States

- bluebird and Celgene will share 50% of U.S. costs and profits - - bluebird to receive milestones and royalties on ex-U.S. sales - CAMBRIDGE, Mass. & SUMMIT, N.J. --(BUSINESS WIRE)--Mar. 28, 2018-- bluebird bio, Inc. (Nasdaq: BLUE) and Celgene Corporation (Nasdaq: CELG) today announced that the

03/07/18
Summary Togglebluebird bio to Present at Investor Conferences in March CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 7, 2018-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
02/21/18
Summary Togglebluebird bio Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress – Company expanding organization and capabilities to prepare three programs for regulatory filing in the next two years – – LentiGlobin in transfusion-dependent β-thalassemia (TDT) planned to be filed for marketing authorization in 2018 – – bb2121 in relapsed/refractory multiple myeloma planned to
02/14/18
Summary Togglebluebird bio Appoints Alison Finger as Chief Commercial Officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 14, 2018-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today appointed Alison Finger as chief
02/02/18
Summary Togglebluebird bio to Present at LEERINK Partners Global Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 2, 2018-- bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that members of the management
01/08/18
Summary Togglebluebird bio Announces Closing of Over-Allotment Option in Public Offering CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 8, 2018-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it has issued an additional

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.

Media Contacts

Stephanie Fagan

Senior Vice President, Corporate Communications

(201) 572-9581

sfagan@bluebirdbio.com

 

Catherine Falcetti

Senior Director, Corporate Communications

(339) 499-9436

cfalcetti@bluebirdbio.com

 

Investor Contact

Elizabeth Pingpank

Associate Director, Corporate Communications

(617) 914-8736

EPingpank@bluebirdbio.com